Table:
Lactic acidosis cases	Non‐cases
n	82	2510
Age (years)	73.5 (9.5)	73.0 (11.5)
Male (%)	65.8%	54.6%
Lactate (mmol/L)	9.3 (3.5)	2.3 (1.7)
Bicarbonate (mmol/L)	11.9 (3.9)	23.5 (5.0)
Type 2 Diabetes, n (% of cohort)	70 (85.4%)	1676 (66.8%)
Users of metformin	42 (60%)	970 (57.9%)
Non‐users of metformin	28 (40%)	706 (42.1%)
AKI stages, n (% of cohort with each stage of AKI)
Stage 0	17 (20.7%)	1569 (62.5%)
Stage 1	16 (19.5%)	508 (20.2%)
Stage 2	25 (30.5%)	266 (10.6)
Stage 3	24 (29.3%)	167 (6.6%)
Baseline eGFR, n (% of cohort)
>60 mL/min/1.73 m2	59 (71.9%)	1979 (78.8%)
30‐59 mL/min/1.73 m2	19 (23.2%)	468 (18.6%)
<30 mL/min/1.73 m2	4 (4.9%)	63 (2.5%)

Continue parse the table with markdown style: |  | Lactic acidosis cases | Non‐cases | 
 | --- | --- | --- | 
 | n | 82 | 2510 | 
 | Age (years) | 73.5 (9.5) | 73.0 (11.5) | 
 | Male (%) | 65.8% | 54.6% | 
 | Lactate (mmol/L) | 9.3 (3.5) | 2.3 (1.7) | 
 | Bicarbonate (mmol/L) | 11.9 (3.9) | 23.5 (5.0) | 
 | Type 2 Diabetes, n (% of cohort) | 70 (85.4%) | 1676 (66.8%) | 
 | Users of metformin | 42 (60%) | 970 (57.9%) | 
 | Non‐users of metformin | 28 (40%) | 706 (42.1%) | 
 | AKI stages, n (% of cohort with each stage of AKI) |  |  | 
 | Stage 0 | 17 (20.7%) | 1569 (62.5%) | 
 | Stage 1 | 16 (19.5%) | 508

(20.2%) | 
 | Stage 2 | 25 (30.5%) | 266 (10.6) | 
 | Stage 3 | 24 (29.3%) | 167 (6.6%) | 
 | Baseline eGFR, n (% of cohort) |  |  | 
 | >60 mL/min/1.73 m2 | 59 (71.9%) | 1979 (78.8%) | 
 | 30‐59 mL/min/1.73 m2 | 19 (23.2%) | 468 (18.6%) | 
 | <30 mL/min/1.73 m2 | 4 (4.9%) | 63 (2.5%) |